Detecting metastatic neck lymph nodes in papillary thyroid carcinoma by 18F-2-deoxyglucose positron emission tomography and Tc-99m tetrofosmin single photon emission computed tomography

Anticancer Research

Volumn 23, Issue 3 C, 2003, Pages 2973-2976

  Wu, Yi Ju ^a   Wu, Hurng Sheng ^a   Yen, Ruoh Fang ^b   Shen, Yeh You ^c   Kao, Chia Hung ^d  

^a SHOW CHWAN MEMORIAL HOSPITAL   (Taiwan)

^b PET Center   (Taiwan)

^c SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

FDG PET; Neck lymph nodes; Papillary thyroid carcinoma; Tc 99m TF SPECT

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; TETROFOSMIN TC 99M; THYROGLOBULIN; THYROTROPIN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MALE; PAPILLARY CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOISOTOPE THERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROIDECTOMY; WHOLE BODY SCINTISCANNING;

ADULT; AGED; CARCINOMA, PAPILLARY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; ORGANOPHOSPHORUS COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN; THYROID NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; WHOLE-BODY COUNTING;

EID: 0042123511     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Mazzaferri EL: Papillary thyroid carcinoma: factors influencing prognosis and current therapy. Semin Oncol 14: 315-332, 1987.
2. McCohaney WH, Hay ID, Wolner LB, Van Heerden JA and Taylor WF: Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc 61: 978-996, 1986.
3. Galloway RJ and Smallridge RC: Imaging in thyroid cancer. Endocrinol Metab Clin North Am 25: 93-113, 1996.
4. Samaan NA, Schultz PN, Haynie TP and Ordonez NG: Pulmonary metastasis of differentiated thyroid carcinoma: treatment results in 101 patients. J Clin Endocrinol Metab 60: 376-380, 1985.
5. 131I whole-body scan. J Nucl Med 40: 986-992, 1999.
6. Feine U, Lietzenmayer R, Hanke J-P, Held J, Wöhrle H and Müller-Schauenburg W: Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 37: 1468-1472, 1996.
7. Fridrich L, Messa C, Landoni C, Lucignani G, Moncayo R, Kendler D, Riccabona G and Fazio F: Whole-body scintigraphy with 99mTc-MIBI, 18F-FDG and 1311 in patients with metastatic thyroid carcinoma. Nucl Med Commun 18: 3-9, 1997.
8. 99mTc-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid 7: 327-335, 1997.
9. Chiu ML, Kronauge JF and Piwnica-Worms D: Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyiso-butylisonitrile) technetium [I] in cultured mouse fibroblast. J Nucl Med 31: 1646-1653, 1990.
10. Higley B, Smith FW, Smith T, Gemmell HG, Das Gupta P, Gvozdanovic DV, Graham D, Hinge D, Davidson J and Lahiri A: Technetium-99m-1,2-bis (bis (2-ethoxyethyl) phosphino) ethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J Nucl Med 34: 30-38, 1993.
11. Harwood J, Clark OH and Dunphy JE: Significance of lymph node metastasis in differentiated thyroid cancer. Am J Surg 136: 107-112, 1978.
12. Kanmaz B, Erdil TY, Yardi OF, Sayman HB, Kabasakal L, Sonmezoglu K, Onsel C, Duren M, Nisli C, Ozcan K and Uslu I: The role of Tc-99m-tetrofosmin in the evaluation of thyroid nodules. Nucl Med Commun 21: 333-339, 2000.
13. Klain M, Maurea S, Cuocolo A, Colao A, Marzano L, Lombardi G and Salvatore M: Technetium-99m tetrofosmin imaging in thyroid diseases: comparison with Tc-99m-pertechnetate, thallium-201 and Tc-99m-methoxyisobutylisonitrile scans. Eur J Nucl Med 23: 1568-1574, 1996.
14. Gallowitsch HJ, Kresnik E, Mikosch P, Pipam W, Gomez I and Lind P: Tc-99m-tetrofosmin scintigraphy: an alternative scintigraphic method for following up differentiated thyroid carcinoma - preliminary results. Nuklearmedizin 35: 230-235, 1996.
15. Lind P, Gallowitsch HJ, Langsteger W, Kresnik E, Mikosch P and Gomez I: Technetium-99m-tetrofosmin whole-body scintigraphy in the follow-up of differentiated thyroid carcinoma. J Nucl Med 38: 348-352, 1997.
16. 131I-negative papillary thyroid carcinoma. J Nucl Med 41: 1010-1015, 2000.
17. Schlüter B, Bohuslavizki KH, Beyer W et al: Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 1311 scan. J Nucl Med 42: 71-76, 2001.